{
  "paper_id": "PMC9169424",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169424/",
  "figures": {
    "figure_0005": {
      "figure_number": "Figure 0005",
      "title": "Fig. 1.",
      "caption": "Flow diagram based on the PRISMA 2020 flow chart summarising the article screening process. * excluded publication type or study design, or letter or comment without relevant primary data.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/886a/9365702/f99ab4569f7a/gr1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/886a/9365702/f99ab4569f7a/gr1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/886a/9365702/f99ab4569f7a/gr1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/886a/9365702/f99ab4569f7a/gr1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig0005",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/886a/9365702/f99ab4569f7a/gr1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9169424/images/figure_0005.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/886a/9365702/f99ab4569f7a/gr1.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Results\nIn total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Study\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\nOverall rating\n\n\nLi J [47]\n\nLow\nHigh\nLow\nLow\nLow\nHigh\nLow\nLow\nLow\nNA\nHigh\nHigh\nNA\nNA\nNA\nHigh\n\n\nOpen in a new tab\n1 = Sources of cases (deaths) and controls (survivors); 2 = Selection of cases and controls; 3 = Definition of cases (outcome); 4 = Definition of controls; 5 = Timing of outcome of interest and exposure measurement (reverse causation); 6 = Measurement of exposure (pre-existing cancer); 7 = Method used to measure exposure (cancer) in cases and controls; 8 = Completeness of follow-up of cohort; 9 = Difference in follow-up between exposed and unexposed members of cohort; 10 = Exclusions due to missing data on other variables; 11 = Comparability of cases and controls on important confounding variables; 12 = Similarity of co-interventions between groups; 13 = Assessment of the presence or absence of prognostic factors; 14 = Covariates are appropriately included in statistical analysis models; 15 = Analysis appropriate to design; NA = not applicable.In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Results\nIn total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Study\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\nOverall rating\n\n\nLi J [47]\n\nLow\nHigh\nLow\nLow\nLow\nHigh\nLow\nLow\nLow\nNA\nHigh\nHigh\nNA\nNA\nNA\nHigh\n\n\nOpen in a new tab\n1 = Sources of cases (deaths) and controls (survivors); 2 = Selection of cases and controls; 3 = Definition of cases (outcome); 4 = Definition of controls; 5 = Timing of outcome of interest and exposure measurement (reverse causation); 6 = Measurement of exposure (pre-existing cancer); 7 = Method used to measure exposure (cancer) in cases and controls; 8 = Completeness of follow-up of cohort; 9 = Difference in follow-up between exposed and unexposed members of cohort; 10 = Exclusions due to missing data on other variables; 11 = Comparability of cases and controls on important confounding variables; 12 = Similarity of co-interventions between groups; 13 = Assessment of the presence or absence of prognostic factors; 14 = Covariates are appropriately included in statistical analysis models; 15 = Analysis appropriate to design; NA = not applicable.In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Results\nIn total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Study\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\nOverall rating\n\n\nLi J [47]\n\nLow\nHigh\nLow\nLow\nLow\nHigh\nLow\nLow\nLow\nNA\nHigh\nHigh\nNA\nNA\nNA\nHigh\n\n\nOpen in a new tab\n1 = Sources of cases (deaths) and controls (survivors); 2 = Selection of cases and controls; 3 = Definition of cases (outcome); 4 = Definition of controls; 5 = Timing of outcome of interest and exposure measurement (reverse causation); 6 = Measurement of exposure (pre-existing cancer); 7 = Method used to measure exposure (cancer) in cases and controls; 8 = Completeness of follow-up of cohort; 9 = Difference in follow-up between exposed and unexposed members of cohort; 10 = Exclusions due to missing data on other variables; 11 = Comparability of cases and controls on important confounding variables; 12 = Similarity of co-interventions between groups; 13 = Assessment of the presence or absence of prognostic factors; 14 = Covariates are appropriately included in statistical analysis models; 15 = Analysis appropriate to design; NA = not applicable.In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Results\nIn total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Study\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\nOverall rating\n\n\nLi J [47]\n\nLow\nHigh\nLow\nLow\nLow\nHigh\nLow\nLow\nLow\nNA\nHigh\nHigh\nNA\nNA\nNA\nHigh\n\n\nOpen in a new tab\n1 = Sources of cases (deaths) and controls (survivors); 2 = Selection of cases and controls; 3 = Definition of cases (outcome); 4 = Definition of controls; 5 = Timing of outcome of interest and exposure measurement (reverse causation); 6 = Measurement of exposure (pre-existing cancer); 7 = Method used to measure exposure (cancer) in cases and controls; 8 = Completeness of follow-up of cohort; 9 = Difference in follow-up between exposed and unexposed members of cohort; 10 = Exclusions due to missing data on other variables; 11 = Comparability of cases and controls on important confounding variables; 12 = Similarity of co-interventions between groups; 13 = Assessment of the presence or absence of prognostic factors; 14 = Covariates are appropriately included in statistical analysis models; 15 = Analysis appropriate to design; NA = not applicable.In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Results\nIn total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Study\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\nOverall rating\n\n\nLi J [47]\n\nLow\nHigh\nLow\nLow\nLow\nHigh\nLow\nLow\nLow\nNA\nHigh\nHigh\nNA\nNA\nNA\nHigh\n\n\nOpen in a new tab\n1 = Sources of cases (deaths) and controls (survivors); 2 = Selection of cases and controls; 3 = Definition of cases (outcome); 4 = Definition of controls; 5 = Timing of outcome of interest and exposure measurement (reverse causation); 6 = Measurement of exposure (pre-existing cancer); 7 = Method used to measure exposure (cancer) in cases and controls; 8 = Completeness of follow-up of cohort; 9 = Difference in follow-up between exposed and unexposed members of cohort; 10 = Exclusions due to missing data on other variables; 11 = Comparability of cases and controls on important confounding variables; 12 = Similarity of co-interventions between groups; 13 = Assessment of the presence or absence of prognostic factors; 14 = Covariates are appropriately included in statistical analysis models; 15 = Analysis appropriate to design; NA = not applicable.In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Results\nIn total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Study\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\nOverall rating\n\n\nLi J [47]\n\nLow\nHigh\nLow\nLow\nLow\nHigh\nLow\nLow\nLow\nNA\nHigh\nHigh\nNA\nNA\nNA\nHigh\n\n\nOpen in a new tab\n1 = Sources of cases (deaths) and controls (survivors); 2 = Selection of cases and controls; 3 = Definition of cases (outcome); 4 = Definition of controls; 5 = Timing of outcome of interest and exposure measurement (reverse causation); 6 = Measurement of exposure (pre-existing cancer); 7 = Method used to measure exposure (cancer) in cases and controls; 8 = Completeness of follow-up of cohort; 9 = Difference in follow-up between exposed and unexposed members of cohort; 10 = Exclusions due to missing data on other variables; 11 = Comparability of cases and controls on important confounding variables; 12 = Similarity of co-interventions between groups; 13 = Assessment of the presence or absence of prognostic factors; 14 = Covariates are appropriately included in statistical analysis models; 15 = Analysis appropriate to design; NA = not applicable.In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Results\nIn total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Study\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\nOverall rating\n\n\nLi J [47]\n\nLow\nHigh\nLow\nLow\nLow\nHigh\nLow\nLow\nLow\nNA\nHigh\nHigh\nNA\nNA\nNA\nHigh\n\n\nOpen in a new tab\n1 = Sources of cases (deaths) and controls (survivors); 2 = Selection of cases and controls; 3 = Definition of cases (outcome); 4 = Definition of controls; 5 = Timing of outcome of interest and exposure measurement (reverse causation); 6 = Measurement of exposure (pre-existing cancer); 7 = Method used to measure exposure (cancer) in cases and controls; 8 = Completeness of follow-up of cohort; 9 = Difference in follow-up between exposed and unexposed members of cohort; 10 = Exclusions due to missing data on other variables; 11 = Comparability of cases and controls on important confounding variables; 12 = Similarity of co-interventions between groups; 13 = Assessment of the presence or absence of prognostic factors; 14 = Covariates are appropriately included in statistical analysis models; 15 = Analysis appropriate to design; NA = not applicable.In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Results\nIn total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Study\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\nOverall rating\n\n\nLi J [47]\n\nLow\nHigh\nLow\nLow\nLow\nHigh\nLow\nLow\nLow\nNA\nHigh\nHigh\nNA\nNA\nNA\nHigh\n\n\nOpen in a new tab\n1 = Sources of cases (deaths) and controls (survivors); 2 = Selection of cases and controls; 3 = Definition of cases (outcome); 4 = Definition of controls; 5 = Timing of outcome of interest and exposure measurement (reverse causation); 6 = Measurement of exposure (pre-existing cancer); 7 = Method used to measure exposure (cancer) in cases and controls; 8 = Completeness of follow-up of cohort; 9 = Difference in follow-up between exposed and unexposed members of cohort; 10 = Exclusions due to missing data on other variables; 11 = Comparability of cases and controls on important confounding variables; 12 = Similarity of co-interventions between groups; 13 = Assessment of the presence or absence of prognostic factors; 14 = Covariates are appropriately included in statistical analysis models; 15 = Analysis appropriate to design; NA = not applicable.In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "Results\nIn total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Study\n1\n2\n3\n4\n5\n6\n7\n8\n9\n10\n11\n12\n13\n14\n15\nOverall rating\n\n\nLi J [47]\n\nLow\nHigh\nLow\nLow\nLow\nHigh\nLow\nLow\nLow\nNA\nHigh\nHigh\nNA\nNA\nNA\nHigh\n\n\nOpen in a new tab\n1 = Sources of cases (deaths) and controls (survivors); 2 = Selection of cases and controls; 3 = Definition of cases (outcome); 4 = Definition of controls; 5 = Timing of outcome of interest and exposure measurement (reverse causation); 6 = Measurement of exposure (pre-existing cancer); 7 = Method used to measure exposure (cancer) in cases and controls; 8 = Completeness of follow-up of cohort; 9 = Difference in follow-up between exposed and unexposed members of cohort; 10 = Exclusions due to missing data on other variables; 11 = Comparability of cases and controls on important confounding variables; 12 = Similarity of co-interventions between groups; 13 = Assessment of the presence or absence of prognostic factors; 14 = Covariates are appropriately included in statistical analysis models; 15 = Analysis appropriate to design; NA = not applicable.In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    },
    {
      "sentence": "In total, 12,225 records were identified and 96 studies satisfied the inclusion criteria (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Analysisa\n\nExposure group\nComparison group\nMeasure of effect\nNumber of studies\nPeople with cancer alive\nPeople with cancer dead\nComparator alive\nComparator dead\nTotalb\n\nPooled effect estimate (95%CI)\nI2 (p-het)\n\n\n\n1c\n\nAny cancer\nNo cancer\nUnadjusted OR\n33\n4839\n1542\n78,786\n9653\n94,820\n2.54 (2.06,3.13)\n83% (<0.001)\n\n\n2\nAny cancer\nNo cancer\nAdjusted OR/RR\n9\n1864\n403\n33,866\n1752\n37,885\n1.66 (1.33,2.08)\n51% (0.038)\n\n\n3\nAny cancer\nNo cancer\nUnadjusted HR\n2\n1244\n483\n12,763\n3022\n17,512\n1.56 (1.43,1.70)\n0% (0.434)\n\n\n4\nAny cancer\nNo cancer\nAdjusted HR\n5\n1964\n465\n23,073\n4032\n29,534\n1.19 (1.02,1.38)\n16% (0.312)\n\n\n5c\n\nAny cancer\nNo cancer\nUnadjusted OR\n1\n0\n2\n96\n63\n161\n6.10 (0.27,137.49)\nn/a\n\n\n6\nAny cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n3\n1003\n112\n236,897\n26311\n263,208b\n\n1.82 (0.63,5.24)\n96% (<0.001)\n\n\n7\nActive cancer\nNo cancer\nUnadjusted OR\n5\n106\n46\n3287\n421\n3860\n2.77 (1.88,4.09)\n0% (0.452)\n\n\n8\nActive cancer\nNo active cancer\nUnadjusted OR\n4\n270\n148\n4162\n1515\n6095\n1.58 (1.11,2.25)\n48% (0.125)\n\n\n9\nActive cancer\nNo active cancer\nAdjusted OR\n1\n173\n66\n455\n129\n823\n1.55 (1.01,2.39)\nn/a\n\n\n10\nActive cancer\nNo active cancer\nUnadjusted HR\n1\n11\n11\n302\n81\n405\n2.77 (1.47,5.22)\nn/a\n\n\n11\nActive cancer\nNo active cancer\nAdjusted HR\n3\n270\n103\n3470\n991\n4834\n1.25 (0.90,1.73)\n51% (0.128)\n\n\n12\nActive cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n60\n32\n98,003\n6182\n104,185b\n\n5.86 (4.43,7.76)\nn/a\n\n\n13\nHaematological cancers\nNo cancer\nUnadjusted OR\n5\n134\n84\n4793\n736\n5747\n4.60 (2.38,8.86)\n61% (0.037)\n\n\n14\nHaematological cancers\nAny COVID diagnosis\nUnadjusted rate ratio\n2\n55\n34\n288,998\n38247\n327,245b\n\n4.19 (1.90,9.26)\n89% (0.003)\n\n\n15\nActive haematological\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n15\n9\n190,995\n32065\n223,060b\n\n2.61 (1.17,5.84)\nn/a\n\n\n16\nLung cancer\nNo cancer\nUnadjusted OR\n3\n25\n17\n1430\n210\n1682\n5.13 (2.70,9.73)\n0% (0.384)\n\n\n17\nLung cancer\nAny COVID diagnosis\nUnadjusted rate ratio\n1\n5\n6\n98,003\n6182\n104,185b\n\n9.19 (5.36,15.77)\nn/a\n\n\n\n\n\nTotal across all analysesd:\n\n80\n12,038\n3563\n1079,379\n131,592\n1225,241\n\n\n\n\n\nOpen in a new tab\n\nNumbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Numbers were estimated for studies that did not report specific numbers of deaths and non-deaths, using total numbers in cancer and comparator groups and reported effect estimates.\n\naForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "aForest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Forest plots for the meta-analyses are shown in Fig. 2, Fig. 3, Fig. 4 and Supplementary Figures 1–18, including additional subgroup analyses and sensitivity analyses using fixed effects rather than random effects for Analyses 1 and 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "In a comparison of unadjusted and adjusted ORs or RRs in six studies (Fig. 2a), the pooled adjusted effect estimate for pre-existing cancer and COVID-19-related death was lower than the corresponding unadjusted estimate (adjusted OR/RR=1.37, 95%CI:1.16–1.61; unadjusted OR/RR=3.30, 95%CI:2.59–4.20).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel a",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "People with a pre-existing diagnosis of cancer had significantly higher risk of death (nine studies, adjusted OR/RR=1.66, 95%CI:1.33–2.08; moderate heterogeneity I2=51%, p = 0.038; Fig. 2b, Analysis 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel b",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were similar for pooled adjusted hazard ratios (five studies, adjusted HR=1.19, 95%CI:1.02–1.38; low heterogeneity I2=16%, p = 0.312; Fig. 2c, Analysis 4).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel c",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The results were also similar for the comparison of people with active and no active cancer (one study, adjusted OR=1.55, 95%CI:1.01–2.39; three studies, adjusted HR=1.25, 95%CI:0.90–1.73; Fig. 3, Analyses 9 and 11).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subgroup analyses to examine sources of heterogeneity were possible for nine studies that adjusted or controlled for age and reported ORs or RRs comparing any cancer to no cancer (Fig. 4; Supplementary Figures 6–8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "We verified that the pooled estimate for these nine studies was similar when using a fixed-effect instead of random effect meta-analysis (pooled fixed-effect OR/RR=1.58, 95%CI:1.37–1.81; Supplementary Figure 18).",
      "figure_references": [
        {
          "figure_number": "Figure 18",
          "panel": "",
          "figure_key": "figure_18"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 1,
    "claims_count": 83,
    "images_downloaded": 1,
    "tables_filtered": 231
  }
}